Join
Live feed
·
PRReleasevia Quantisnow
Century Therapeutics Inc. logo

Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

ByQuantisnow·Wall Street's wire, on your screen.
IPSC· Century Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IPSC (Century Therapeutics Inc.) and more on Quantisnow.